Literature DB >> 11687953

VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression.

M L George1, M G Tutton, F Janssen, A Arnaout, A M Abulafi, S A Eccles, R I Swift.   

Abstract

We aimed to assess the relationship of the angiogenic cytokines VEGF-A, VEGF-C, and VEGF-D and their receptors VEGFR-2 and VEGFR-3 in the adenoma-carcinoma sequence and in metastatic spread of colorectal cancer (CRC). mRNA expression levels were measured using semi-quantitative reverse transcription polymerase chain reaction in 70 CRC (35 with paired mucosae) and 20 adenomatous polyps. Immunohistochemistry and ELISA assessed protein expression. VEGF-D mRNA expression was significantly lower in both polyps and CRCs compared with normal mucosa (P=.0002 and.002, respectively), whereas VEGF-A and VEGF-C were significantly raised in CRCs (P=.006 and.004, respectively), but not polyps (P=.22 and P=.5, respectively). Receptor expression was similar in tumor tissue and normal mucosae. Tumors with lymph node metastases had significantly higher levels of VEGF-A compared with non-metastatic tumors (P=.043). There was no association between VEGF-C or VEGF-D and lymphatic spread. The decrease in VEGF-D occurring in polyps and carcinomas may allow the higher levels of VEGF-A and VEGF-C to bind more readily to the VEGF receptors, and produce the angiogenic switch required for tumor growth. Increased expression of VEGF-A within CRCs was associated with lymphatic metastases, and therefore, this member of the VEGF family may be the most important in determining metastatic spread.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687953      PMCID: PMC1506210          DOI: 10.1038/sj.neo.7900186

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  43 in total

1.  Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers.

Authors:  S Nakata; K Ito; M Fujimori; K Shingu; S Kajikawa; W Adachi; I Matsuyama; S Tsuchiya; M Kuwano; J Amano
Journal:  Int J Cancer       Date:  1998-04-17       Impact factor: 7.396

Review 2.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

3.  Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa.

Authors:  T André; L Kotelevets; J C Vaillant; A M Coudray; L Weber; S Prévot; R Parc; C Gespach; E Chastre
Journal:  Int J Cancer       Date:  2000-04-15       Impact factor: 7.396

4.  Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?

Authors:  M L George; S A Eccles; M G Tutton; A M Abulafi; R I Swift
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

5.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer.

Authors:  R Valtola; P Salven; P Heikkilä; J Taipale; H Joensuu; M Rehn; T Pihlajaniemi; H Weich; R deWaal; K Alitalo
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

6.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation.

Authors:  A J Leu; D A Berk; A Lymboussaki; K Alitalo; R K Jain
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

7.  Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12.

Authors:  M H Wei; N C Popescu; M I Lerman; M J Merrill; D B Zimonjic
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

8.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

Authors:  Y Takahashi; Y Kitadai; C D Bucana; K R Cleary; L M Ellis
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

9.  Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.

Authors:  P Salven; A Lymboussaki; P Heikkilä; H Jääskela-Saari; B Enholm; K Aase; G von Euler; U Eriksson; K Alitalo; H Joensuu
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

10.  VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development.

Authors:  E Kukk; A Lymboussaki; S Taira; A Kaipainen; M Jeltsch; V Joukov; K Alitalo
Journal:  Development       Date:  1996-12       Impact factor: 6.868

View more
  60 in total

1.  Rationale for combining biotherapy in the treatment of advanced colon cancer.

Authors:  Deirdre J Cohen; Howard S Hochster
Journal:  Gastrointest Cancer Res       Date:  2008-05

2.  One-carbon metabolites, B vitamins and associations with systemic inflammation and angiogenesis biomarkers among colorectal cancer patients: results from the ColoCare Study.

Authors:  Cornelia M Ulrich; Mary Playdon; Rama Kiblawi; Andreana N Holowatyj; Biljana Gigic; Stefanie Brezina; Anne J M R Geijsen; Jennifer Ose; Tengda Lin; Sheetal Hardikar; Caroline Himbert; Christy A Warby; Jürgen Böhm; Martijn J L Bours; Fränzel J B van Duijnhoven; Tanja Gumpenberger; Dieuwertje E Kok; Janna L Koole; Eline H van Roekel; Petra Schrotz-King; Arve Ulvik; Andrea Gsur; Nina Habermann; Matty P Weijenberg; Per Magne Ueland; Martin Schneider; Alexis Ulrich
Journal:  Br J Nutr       Date:  2020-02-05       Impact factor: 3.718

3.  Promotion of metastasis of thyroid cancer cells via NRP-2-mediated induction.

Authors:  Dom-Gene Tu; Wen-Wei Chang; Ming-Shiou Jan; Chi-Wen Tu; Yin-Che Lu; Chien-Kuo Tai
Journal:  Oncol Lett       Date:  2016-09-20       Impact factor: 2.967

4.  Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer.

Authors:  Ryo Morita; Kazuhiro Sato; Mariko Nakano; Hajime Miura; Hidesato Odaka; Kiyoshi Nobori; Toshimitsu Kosaka; Masaaki Sano; Hiroyuki Watanabe; Takanobu Shioya; Hiroshi Ito
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-17       Impact factor: 4.553

Review 5.  Molecular mechanisms of lymphatic metastasis in solid tumors of the gastrointestinal tract.

Authors:  Melanie C Langheinrich; Vera Schellerer; Aristotelis Perrakis; Clemens Lohmüller; Claus Schildberg; Elisabeth Naschberger; Michael Stürzl; Werner Hohenberger; Roland S Croner
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05

6.  Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.

Authors:  Asish K Ghosh; Charla R Secreto; Traci R Knox; Wei Ding; Debabrata Mukhopadhyay; Neil E Kay
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

7.  The importance of -460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer.

Authors:  Torben F Hansen; Karen-Lise G Spindler; Karen A Lorentzen; Dorte A Olsen; Rikke F Andersen; Jan Lindebjerg; Ivan Brandslund; Anders Jakobsen
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-11       Impact factor: 4.553

8.  Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.

Authors:  A Abajo; J Rodriguez; N Bitarte; R Zarate; V Boni; M Ponz; A Chopitea; E Bandres; J Garcia-Foncillas
Journal:  Br J Cancer       Date:  2010-10-12       Impact factor: 7.640

9.  Anti-human vascular endothelial growth factor (VEGF) antibody selection for immunohistochemical staining of proliferating blood vessels.

Authors:  Chris M van der Loos; Lorine B Meijer-Jorna; Marloes E C Broekmans; Hanneke P H M Ploegmakers; Peter Teeling; Onno J de Boer; Allard C van der Wal
Journal:  J Histochem Cytochem       Date:  2010-02       Impact factor: 2.479

10.  Preoperative serum levels of serum VEGF-C is associated with distant metastasis in colorectal cancer patients.

Authors:  Andrew A Alabi; Aravind Suppiah; Leigh A Madden; John R Monson; John Greenman
Journal:  Int J Colorectal Dis       Date:  2008-12-16       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.